ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2012
Clinical management of ESBL-producing Enterobacteriaceae: the insidious role of fluoroquinolones.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Can flow cytometry be an alternative method for the detection of antimicrobial resistance?African health sciences · 2024Article
- Article
- Managing ESBL-producing Enterobacteriaceae-related urinary tract infection in primary care: a tool kit for general practitioners.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- A toolkit for the management of infection or colonization by extended-spectrum beta-lactamase producing Enterobacteriaceae in Italy: implementation and outcome of a European project.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Are Fluoroquinolones Appropriate for the Treatment of Extended-Spectrum β-Lactamase-Producing Gram-Negative Bacilli?The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During a review of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in our Hospital, a huge number of inadequate antimicrobial therapies emerged. The aim of this study is to assess the factors related to such inadequacy. This retrospective analysis was performed on isolates reported by the microbiology laboratory. Medical records were analyzed to assess adequate treatment; inadequacy was evaluated as overall therapy, antibiotic choice, dosage and length of treatment. Linear regression and multivariate analysis were performed to assess any association. One hundred and fifty isolates were analyzed. They were more commonly isolated from urinary samples and from patients admitted to the Internal Medicine Department; E. coli was the most commonly isolated pathogen. The rate of inadequacy was 60.67%. Fluoroquinolones seem to be the main class responsible. Ceftriaxone, teicoplanin, tigecycline and amoxicillin-clavulanate are other antibiotics inadequately prescribed. Clinical management of these infections should be better tailored: the knowledge of pathogens should be implemented and the use of diagnostic tools, such as microbiology results, must be optimized. In particular, the prescription of each antibiotic course (and above all of regimens containing fluoroquinolones) should be performed not on a routine basis, but after careful assessment of each case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.